- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04176198
Eine Studie über orales TP-3654 bei Patienten mit Myelofibrose
Eine Open-Label-, Dosiseskalations-, Sicherheits-, pharmakokinetische und pharmakodynamische Studie der Phase 1/2 zu oralem TP-3654 bei Patienten mit primärer oder sekundärer Myelofibrose mit mittlerem oder hohem Risiko
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Arm 1 will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive treatment with a JAK inhibitor.
Arm 2 will enroll patients who are on a stable dose of ruxolitinib, but who have either lost response or had a suboptimal or plateau in response.
Arm 3 will enroll patients who have been previously treated with a JAK inhibitor (except momelotinib)
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: Reyna Bishop
- Telefonnummer: 617-674-6800
- E-Mail: reyna.bishop@us.sumitomo-pharma.com
Studieren Sie die Kontaktsicherung
- Name: Jordan Simpson
- E-Mail: jordan.simpson@us.sumitomo-pharma.com
Studienorte
-
-
-
Adelaide, Australien
- Rekrutierung
- Icon Cancer Centre (Ashford Cancer Centre Research)
-
Kontakt:
- Stanley Cheung, MD
- E-Mail: Stanley.Cheung@icon.team
-
-
South Australia
-
Adelaide, South Australia, Australien
- Rekrutierung
- Royal Adelaide Hospital
-
Kontakt:
- Christine Hoare
- E-Mail: christine.hoare@sa.gov.au
-
-
Victoria
-
Box Hill, Victoria, Australien
- Rekrutierung
- Eastern Health Box Hill Hospital
-
Kontakt:
- SMPA Investigative Site
-
Clayton, Victoria, Australien
- Rekrutierung
- Monash University
-
Kontakt:
- SMPA Investigative Site
-
Fitzroy, Victoria, Australien
- Rekrutierung
- St Vincent's Hospital Melbourne
-
Kontakt:
- SMPA Investigative Site
-
Melbourne, Victoria, Australien
- Rekrutierung
- Peter McCallum Center
-
Kontakt:
- SMPA Investigative Site
-
Richmond, Victoria, Australien
- Rekrutierung
- Epworth Healthcare
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Antwerp, Belgien, 2020
- Rekrutierung
- ZNA Cadix
-
Kontakt:
- SMPA Investigative Site
-
Antwerp, Belgien, 2030
- Rekrutierung
- ZNA Middelheim
-
Kontakt:
- SMPA Investigative Site
-
Ghent, Belgien, 9000
- Rekrutierung
- Universitair Ziekenhuis Gent
-
Kontakt:
- SMPA Investigative Site
-
Liège, Belgien, 4000
- Rekrutierung
- CHU de Liege
-
Kontakt:
- SMPA Investigative Site
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgien, 3000
- Rekrutierung
- University Hospitals Leuven
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Halle, Deutschland
- Rekrutierung
- Universitätsmedizin Halle
-
Kontakt:
- SMPA Investigative Site
-
Lübeck, Deutschland
- Rekrutierung
- Universitätsklinikum Schleswig-Holstein
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Amiens, Frankreich, 80054
- Rekrutierung
- Centre Hospitalier Universitaire D'Amiens
-
Kontakt:
- SMPA Investigative Site
-
Angers, Frankreich, 9000
- Rekrutierung
- CHU Angers
-
Kontakt:
- SMPA Investigative Site
-
Lyon, Frankreich, 69495
- Rekrutierung
- Centre Hospitalier Lyon Sud
-
Kontakt:
- SMPA Investigative Site
-
Nice, Frankreich, 06200
- Rekrutierung
- Hospitalier Universitaire (CHU) de Nice - Hopital de l'Archet
-
Kontakt:
- SMPA Investigative Site
-
Nîmes, Frankreich, 30029
- Rekrutierung
- Institut de cancerologie du Gard
-
Kontakt:
- SMPA Investigative Site
-
Nîmes, Frankreich
- Rekrutierung
- Institut de cancerologie du Gard
-
Kontakt:
- SMPA Investigative Site
-
Paris, Frankreich, 75010
- Rekrutierung
- Hospital Saint Louis
-
Kontakt:
- SMPA Investigative Site
-
Poitiers, Frankreich, 86021
- Rekrutierung
- University Hospital of Poitiers
-
Kontakt:
- SMPA Investigative Site
-
Villejuif, Frankreich, 94805
- Rekrutierung
- Institut Gustave Roussy
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Alessandria, Italien, 15121
- Rekrutierung
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
-
Kontakt:
- SMPA Investigative Site
-
Aviano, Italien, 33081
- Rekrutierung
- Istituto Nazionale Tumori, IRCCS Centro di Riferimento Oncologico di Aviano
-
Bologna, Italien, 40138
- Rekrutierung
- IRCCS Azienda Ospedaliero -Universitaria Di Bologna - Dipartimento Malattie Oncologiche ed Ematologiche - UO Ematologia
-
Kontakt:
- SMPA Investigative Site
-
Brescia, Italien
- Rekrutierung
- ASST - Spedali Civili di Brescia
-
Kontakt:
- SMPA Investigative Site
-
Meldola, Italien, 47014
- Rekrutierung
- IRCCS istituto Romagnolo per lo studio dei tumori "Dino Amadori"
-
Kontakt:
- SMPA Investigative Site
-
Milan, Italien, 20122
- Rekrutierung
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Kontakt:
- SMPA Investigative Site
-
Torino, Italien, 10126
- Rekrutierung
- Azienda Ospedaliera Universitaria Citta' Della Salute E della Scienza di Torino
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Aichi, Japan
- Rekrutierung
- Aichi Medical University Hospital
-
Kontakt:
- Akiyoshi Takami
- Telefonnummer: 0561-62-3311
- E-Mail: takami.akiyoshi.490@mail.aichi-med-u.ac.jp
-
Aomori, Japan
- Rekrutierung
- Aomori Prefectural Central Hospital
-
Kontakt:
- Tomoaki Akagi, MD
- Telefonnummer: 017-726-8111
- E-Mail: tomakagi@med.pref.aomori.jp
-
Chiba, Japan
- Rekrutierung
- National Cancer Center Hospital East
-
Kontakt:
- Junichiro Yuda, MD
- Telefonnummer: 04-7133-1111
- E-Mail: jyuda@east.ncc.go.jp
-
Fukuoka, Japan
- Rekrutierung
- Kyushu University Hospital
-
Kontakt:
- Takuji Yamauchi, MD
- Telefonnummer: 092-641-1151
- E-Mail: yamauchi.takuji.355@m.kyushu-u.ac.jp
-
Hokkaido, Japan
- Rekrutierung
- Hokkaido University Hospital
-
Kontakt:
- Takanori Teshima, MD
- Telefonnummer: 011-716-1161
- E-Mail: teshima@med.hokudai.ac.jp
-
Kamakura, Japan, 247-8533
- Rekrutierung
- Shonan Kamakura General Hospital
-
Kontakt:
- Tomiteru Togano, MD
- Telefonnummer: 0467-46-1717
- E-Mail: t_togano@shonankamakura.or.jp
-
Miyazaki, Japan
- Rekrutierung
- University of Miyazaki Hospital
-
Kontakt:
- Kazuya Shimoda, MD
- Telefonnummer: 0985-85-1510
- E-Mail: kshimoda@med.miyazaki-u.ac.jp
-
Okayama, Japan
- Rekrutierung
- Okayama University Hospital
-
Kontakt:
- Noboru Asada, MD
- Telefonnummer: 086-223-7151
- E-Mail: nasada@okayama-u.ac.jp
-
Osaka, Japan
- Rekrutierung
- The University of Osaka Hospital
-
Kontakt:
- Michiko Ichii, MD
- Telefonnummer: 06-6879-5111
-
Saitama, Japan
- Abgeschlossen
- Saitama Medical Center
-
Sendai, Japan
- Rekrutierung
- Tohoku University Hospital
-
Kontakt:
- Noriko Fukuhara, MD
- Telefonnummer: 022-717-7000
-
Shizuoka, Japan
- Abgeschlossen
- Shizuoka Cancer Center
-
Tokyo, Japan, 160-0023
- Rekrutierung
- Tokyo Medical University Hospital
-
Kontakt:
- Daigo Akahane, MD
- Telefonnummer: 03-3342-6111
- E-Mail: dakahane@tokyo-med.ac.jp
-
Tokyo, Japan
- Rekrutierung
- Juntendo University Hospital
-
Kontakt:
- Shuichi Shirane, MD
- Telefonnummer: 03-3813-3111
- E-Mail: sshirane@juntendo.ac.jp
-
Tokyo, Japan, 179-0072
- Rekrutierung
- Nerima Hikarigaoka Hospital
-
Kontakt:
- Akihiko Gotoh, MD
- Telefonnummer: 03-3979-3611
- E-Mail: akgotou@juntendo.ac.jp
-
Tsu, Japan
- Rekrutierung
- Mie University Hospital
-
Kontakt:
- Yuka Sugimoto, MD
- Telefonnummer: 059-232-1111
- E-Mail: yuka2@clin.medic.mie-u.ac.jp
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 1N4
- Rekrutierung
- University of Calgary
-
Kontakt:
- Sonia Cerquozzi
- E-Mail: sonia.cerquozzi@albertahealthservices.ca
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6T 1Z3
- Rekrutierung
- University of British Columbia
-
Kontakt:
- SMPA Investigative Site
-
Vancouver, British Columbia, Kanada, V6T 1Z3
- Rekrutierung
- St. Paul's Hospital Hematology/Oncology Research
-
Kontakt:
- Kelsi Sorensen
- Telefonnummer: 604-682-2344
- E-Mail: ksorensen1@providencehealth.bc
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8V 5C2
- Rekrutierung
- Juravinski Cancer Center
-
Kontakt:
- SMPA Investigative Site
-
Toronto, Ontario, Kanada, M5G 2M9
- Rekrutierung
- Princess Margaret Cancer Center
-
Kontakt:
- Vikas Gupta
- E-Mail: vikas.gupta@uhn.ca
-
-
Quebec
-
Montreal, Quebec, Kanada, H3T 1E2
- Rekrutierung
- Jewish General Hospital
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Barcelona, Spanien
- Rekrutierung
- Hospital Universitario y Politecnico La Fe
-
Kontakt:
- SMPA Investigative Site
-
Barcelona, Spanien
- Rekrutierung
- Institut Catala d'Oncologia
-
Kontakt:
- SMPA Investigative Site
-
Salamanca, Spanien
- Rekrutierung
- Hospital Universitario de Salamanca
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35294
- Rekrutierung
- University of Alabama
-
Kontakt:
- Tiffany Hill
- Telefonnummer: 205-934-9591
-
-
Arizona
-
Tucson, Arizona, Vereinigte Staaten, 85724
- Rekrutierung
- The University of Arizona Cancer Center
-
Kontakt:
- Audrey Johnson
- Telefonnummer: 520-694-9084
- E-Mail: audieejayy@arizona.edu
-
-
California
-
Duarte, California, Vereinigte Staaten, 91010
- Rekrutierung
- City of Hope
-
Kontakt:
- Michelle Velasquez
- Telefonnummer: 626-218-3524
- E-Mail: mvelaszuez@coh.org
-
Los Angeles, California, Vereinigte Staaten, 90033
- Rekrutierung
- University of Southern California
-
Kontakt:
- Shirley Sian
- Telefonnummer: 323-865-0456
- E-Mail: sian_s@med.usc.edu
-
Newport Beach, California, Vereinigte Staaten, 92663
- Rekrutierung
- Hoag Family Cancer Institute
-
Kontakt:
- Patrice Jones
- Telefonnummer: 949-764-5501
- E-Mail: patrice.jones@hoag.org
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten, 80218
- Rekrutierung
- Blood Cancer Center
-
Kontakt:
- Brooke Rhodes
- E-Mail: Brookerhodes@sarahcannon.com
-
-
Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06510
- Rekrutierung
- Yale School of Medicine
-
Kontakt:
- Farah Fasihuddin
- Telefonnummer: 203-494-4610
- E-Mail: farah.fasihuddin@yale.edu
-
-
Florida
-
Gainesville, Florida, Vereinigte Staaten, 32608
- Abgeschlossen
- University of Florida Health Shands Cancer Hospital
-
Miami, Florida, Vereinigte Staaten, 33136
- Rekrutierung
- University of Miami
-
Kontakt:
- Alessia Zoso
- Telefonnummer: 305-243-0327
- E-Mail: azoso@miami.edu
-
Miami, Florida, Vereinigte Staaten, 33176
- Rekrutierung
- Baptist Health - Miami Cancer Institute
-
Kontakt:
- Firas El Chaer, MD
- Telefonnummer: 786-596-2000
- E-Mail: firas.elchaer@baptisthealth.net
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Rekrutierung
- Emory University
-
Kontakt:
- Suzanne Scott
- Telefonnummer: 404-778-4334
- E-Mail: suzanne.e.scott@emory.edu
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60637
- Rekrutierung
- University of Chicago
-
Kontakt:
- Howie Weiner
- E-Mail: HWeiner@bsd.uchicago.edu
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- Rekrutierung
- University of Maryland
-
Kontakt:
- Maria Baer, MD
- Telefonnummer: 410-328-8708
- E-Mail: mbaer@umm.edu
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Rekrutierung
- Massachusetts General Hospital
-
Kontakt:
- Gabriela Hobbs, MD
- E-Mail: ghobbs@mgb.org
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- Rekrutierung
- University of Michigan
-
Kontakt:
- Kelsey Bolin
- Telefonnummer: 734-936-2193
- E-Mail: kntillma@med.umich.edu
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- Rekrutierung
- University of Minnesota
-
Kontakt:
- Naveen Premnath, MD
- E-Mail: premn007@umn.edu
-
-
Missouri
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Rekrutierung
- Washington University of Medicine
-
Kontakt:
- Nicole Gaudin
- Telefonnummer: 314-747-7960
- E-Mail: nrgaudin@wustl.edu
-
-
New Jersey
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Rekrutierung
- John Theurer Cancer Center at Hackensack University Medical Center
-
Kontakt:
- Parita Patel
- Telefonnummer: 551-996-5900
- E-Mail: parita.patel@hmhn.org
-
-
New York
-
Buffalo, New York, Vereinigte Staaten, 14263
- Abgeschlossen
- Roswell Park Comprehensive Cancer Center
-
New York, New York, Vereinigte Staaten, 10065
- Rekrutierung
- Memorial Sloan Kettering Cancer Center
-
Kontakt:
- Tamanna Haque, MD
- E-Mail: haquet1@mskcc.org
-
New York, New York, Vereinigte Staaten, 10029
- Rekrutierung
- Icahn School of Medicine at Mount Sinai
-
Kontakt:
- Gabriela Bello
- E-Mail: gabriela.bello@mssm.edu
-
New York, New York, Vereinigte Staaten, 10065
- Rekrutierung
- Weill Cornell Medical Center
-
Kontakt:
- Penina Steward
- Telefonnummer: 212-746-1858
- E-Mail: pes4006@med.cornell.edu
-
The Bronx, New York, Vereinigte Staaten, 10461
- Rekrutierung
- Montefiore Cancer Center
-
Kontakt:
- Olivia Orellano
- E-Mail: oorellano@montefiore.org
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Rekrutierung
- Duke Cancer Institute
-
Kontakt:
- Ben Dosan
- E-Mail: benjamin.dosan@duke.edu
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Rekrutierung
- Ohio State University
-
Kontakt:
- Molly Brandenburg
- Telefonnummer: 614-366-7951
- E-Mail: Molly.Brandenburg@osumc.edu
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Rekrutierung
- Medical University of South Carolina
-
Kontakt:
- Jared Hortman
- E-Mail: hortman@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Rekrutierung
- Vanderbilt University
-
Kontakt:
- SMPA Investigative Site
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Rekrutierung
- Tri-Star Centennial Medical Center
-
Kontakt:
- Brooke Rhodes
- E-Mail: brooke.rhodes@sarahcannon.com
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77054
- Rekrutierung
- MD Anderson Cancer Center
-
Kontakt:
- Kurt Schroeder
- Telefonnummer: 713-745-2232
- E-Mail: kdschroe@mdanderson.org
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84112
- Rekrutierung
- Huntsman Cancer Institute
-
Kontakt:
- Nicole Fisher
- Telefonnummer: 801-587-7000
- E-Mail: nicole.fisher@hci.utah.edu
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22903
- Rekrutierung
- University of Virginia Cancer Center
-
Kontakt:
- Avani Hopkins
- Telefonnummer: 434-243-8108
- E-Mail: AJH7JQE@uvahealth.org
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98109
- Rekrutierung
- University of Washington - Fred Hutchinson Cancer Center
-
Kontakt:
- Anna Halpern
- E-Mail: halpern2@uw.edu
-
-
-
-
-
Lincoln, Vereinigtes Königreich
- Rekrutierung
- Lincoln County Hospital
-
Kontakt:
- SMPA Investigative Site
-
Lincoln, Vereinigtes Königreich
- Rekrutierung
- United Lincolnshire Hospitals NHS Trust - Pilgrim Hospital
-
Kontakt:
- SMPA Investigative Site
-
London, Vereinigtes Königreich
- Rekrutierung
- University College London Hospital's NHS foundation Trust
-
Kontakt:
- SMPA Investigative Site
-
Oxford, Vereinigtes Königreich
- Rekrutierung
- Oxford University Hospitals NHS Foundation
-
Kontakt:
- SMPA Investigative Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Patients must meet all of the following inclusion criteria to be eligible:
Nuvisertib (TP-3654) Monotherapy Arm:
- Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF and intermediate or high-risk primary or secondary MF
- Previously treated with JAK inhibitor(s) and is intolerant, resistant, refractory or has lost response to the JAK inhibitor(s) or is ineligible to be treated with JAK inhibitor
- Fulfill the following clinical laboratory parameters:
- Platelet count ≥ 25 x 10^9 /L, without assistance of growth factors or platelet transfusions
- ANC ≥ 1 x 10^9/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5%
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI or CT scan) within 2 weeks prior to Cycle 1 Day 1.
- Dose escalation: At least 2 symptoms measurable (score ≥ 1) using the MF-SAF
- Dose expansion: At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF
Nuvisertib (TP-3654) + Ruxolitinib Arm:
- Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF and intermediate or high-risk primary or secondary MF
- On ruxolitinib treatment for ≥ 6 months, and on a stable dose of ruxolitinib (5 to 25 mg BID) for ≥ 8 weeks prior to the first dose of nuvisertib, but has either lost response or had a suboptimal or plateau in response
- Fulfills the following clinical laboratory parameters:
- Platelet count ≥ 50 × 10^9/L (without assistance of growth factors or platelet transfusions)
- ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5% at screening
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
- At least 2 symptoms measurable with each score ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
Nuvisertib (TP-3654) + Momelotinib Arm
- Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF and intermediate or high-risk primary or secondary MF
- Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for ≥ 12 weeks, or ≥ 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of ≥ 4 units of red blood cells in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma
- Fulfills the following clinical laboratory parameters:
- Anemic, defined as Hb <10 g/dL or requiring RBC transfusion at baseline
- Platelet count ≥ 50 × 109/L (without assistance of growth factors or platelet transfusions)
- ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5% at screening
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
- At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
Patients meeting any one of these exclusion criteria will be prohibited from participating in this study:
Nuvisertib (TP-3654) Monotherapy Arm:
- Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or not recovered adequately from from surgery prior to first dose.
- Splenic irradiation within 6 months prior to Screening or prior splenectomy.
- Prior allogeneic stem cell transplant within the last 6 months.
- Eligible for allogeneic bone marrow or stem cell transplantation.
- Unresolved Grade ≥ 2 non-hematological toxicity related to prior treatment
- History of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; left ventricular ejection fraction (LVEF) < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1.
- Corrected QT interval > 480msec.
- Prior or concurrent malignancy that could interfere with the investigational regime.
- Known history of chronic liver disease, e.g. portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1.
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Exhibited allergic reactions or sensitivity to nuvisertib, or similar compound.
- Medical condition or GI tract surgery that could impair absorption or result in short bowel syndrome with diarrhea.
- Systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding.
- Pregnant or breastfeeding
- Currently receiving any other investigational agent.
Nuvisertib (TP-3654) + Ruxolitinib Arm:
- Received previous systemic antineoplastic therapy (other than ruxolitinib) or any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Note: Prior treatment with nuvisertib is not allowed. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited)
- Known allergic reactions or sensitivity to nuvisertib, or similar compound.
- Splenic irradiation within 6 months prior to Screening or prior splenectomy
- Prior allogeneic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
- Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible.)
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately prior to first dose.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed).
- Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
- History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF <45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
- Corrected QTcF of > 480 msec
- Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
- History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
- Pregnant or breastfeeding
Nuvisertib (TP-3654) + Momelotinib Arm:
- Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Notes: Prior treatment with momelotinib or nuvisertib is not allowed; in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week. Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper; hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
- Known allergic reactions or sensitivity to nuvisertib, momelotinib, or any structurally similar drug, or to any component of the formulations of either study intervention
- Splenic irradiation within 6 months prior to screening or prior splenectomy
- Prior allogenic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
- Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible).
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately from surgery prior to first dose.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed)
- Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
- Presence of Grade ≥ 2 peripheral neuropathy
- History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
- Corrected QTcF of > 480 msec
- Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
- History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
- Pregnant or breastfeeding
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Arm 1: Nuvisertib (TP-3654)
|
Oral PIM Inhibitor
Andere Namen:
|
|
Experimental: Arm 2: Nuvisertib (TP-3654) zusätzlich zu Ruxolitinib
|
Oral PIM Inhibitor
Andere Namen:
Oral JAK inhibitor
Andere Namen:
|
|
Experimental: Arm 3: Nuvisertib (TP-3654) in Kombination mit Momelotinib
|
Oral PIM Inhibitor
Andere Namen:
Oral JAK inhibitor
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Determine the incidence of dose-limiting toxicities (DLTs)
Zeitfenster: 28 days
|
Number of participants with DLTs |
28 days
|
|
Determine the incidence of treatment emergent adverse events
Zeitfenster: From start of treatment to end of study
|
Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events |
From start of treatment to end of study
|
|
Assess patients for any evidence of preliminary activity by determining the number of patients with ≥ 35% spleen volume reduction (SVR35)
Zeitfenster: From start of treatment to end of study
|
Number of participants with ≥ 35% spleen volume reduction (SVR35) |
From start of treatment to end of study
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of participants achieving objective response by IWG-MRT response criteria
Zeitfenster: From start of treatment to end of study
|
Number of participants achieving complete remission, partial remission, clinical improvement, progressive disease and stable disease. |
From start of treatment to end of study
|
|
Number of participants who have ≥ 25% spleen volume reduction
Zeitfenster: Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.
|
Number of participants who have ≥ 25% spleen volume reduction compared to baseline |
Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.
|
|
Number of participants with ≥ 50% improvement in total symptom score (TSS50) at week 24
Zeitfenster: 24 weeks
|
Number of participants who have ≥ 50% total symptom score reduction by MFSAF compared to baseline after 24 weeks of treatment. |
24 weeks
|
|
Determine the change in Patient Global Impression of Change (PGIC) at week 24 through end of study.
Zeitfenster: After 24 weeks of treatment to end of study
|
Change in PGIC score |
After 24 weeks of treatment to end of study
|
|
Determine the incidence of QT interval changes
Zeitfenster: 25 hours
|
Changes in QT interval and heart rhythm |
25 hours
|
|
Establish the half-life (t½) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Zeitfenster: 24 hours
|
The estimate of time for the nuvisertib concentration or amount to be reduced by half |
24 hours
|
|
Establish the Area under the plasma concentration versus time curve (AUC) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Zeitfenster: 24 hours
|
The amount of drug exposure over 24 hours period after administration |
24 hours
|
|
Establish the Peak Plasma Concentration (Cmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Zeitfenster: 24 hours
|
The maximum nuvisertib concentration after administration |
24 hours
|
|
Establish the Time of Maximum concentration observed (tmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Zeitfenster: 24 hours
|
The time to reach maximum nuvisertib concentration |
24 hours
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Anzahl der Patienten mit einer Verringerung der Knochenmarkfibrose
Zeitfenster: Alle 24 Wochen bis zum Ende des Studiums
|
Alle 24 Wochen bis zum Ende des Studiums
|
|
|
Nuvisertib-Kombinationsarme: Bewerten Sie den Anstieg des Hämoglobins um ≥ 1,5 oder ≥ 2 g/dl gegenüber dem Ausgangswert
Zeitfenster: Vom Beginn der Behandlung bis zum Ende des Studiums
|
Vom Beginn der Behandlung bis zum Ende des Studiums
|
|
|
Nuvisertib-Kombinationsarme: Beurteilung des Unabhängigkeitsstatus der Erythrozytentransfusion oder etwaiger Anforderungsänderungen
Zeitfenster: Vom Beginn der Behandlung bis zum Ende des Studiums
|
Vom Beginn der Behandlung bis zum Ende des Studiums
|
|
|
Nuvisertib -Monotherapie: Veränderungen der Thrombozytenzahl im Laufe der Zeit bei Patienten mit Thrombozytzahl <100 x 10^9/l
Zeitfenster: Von Beginn der Behandlung bis zum Ende der Studie
|
Von Beginn der Behandlung bis zum Ende der Studie
|
|
|
Study potential pharmacodynamic (PD) markers of nuvisertib
Zeitfenster: 12 months
|
Evaluate exploratory biomarkers, including change in protein phosphorylation and inflammatory cytokines, in peripheral blood samples and bone marrow biopsy samples. |
12 months
|
|
Establish overall survival
Zeitfenster: From start of treatment to end of study
|
The time interval from treatment start date to date of death from any cause |
From start of treatment to end of study
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- BBI-TP-3654-102
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .